Merck will reduce its workforce by approximately 6,000 employees in “some areas of our global workforce,” the New Jersey ...

Merck Q2 earnings beat estimates but revenue fell short. Gardasil sales dropped while Keytruda and other treatments drove ...

Merck said on Tuesday it was extending its pause on Gardasil shipments to China until at least the end of 2025 due to ...

Shipments to China are now paused through the end of 2025, dragging global sales of the HPV vaccine down 55% last quarter.

A PD-L1xVEGF bispecific antibody from China’s ImmuneOnco Biopharmaceuticals has shown early promise in shrinking lung tumors, ...

Merck & Co. is slashing $3 billion from its annual spending as it braces for off-brand competition to its cancer drug ...

Facing an end to Keytruda's market exclusivity, the company will cut $3 billion in costs that it plans to redeploy in support ...

We recently published 13 Stocks That Jim Cramer Recently Talked About. Merck & Co., Inc. (NYSE:MRK) is one of the stocks Jim ...

Keytruda is used for the treatment of different types of cancers, including lung, head & neck, and melanoma among others. It has become the most important drug for Merck, given its contribution to ...

Merck MRK 1.73% & Co.’s new cancer drug Keytruda improved the survival odds of patients with the skin cancer melanoma compared with Bristol-Myers Squibb Co.’s BMY 1.00% Yervoy, in the first ...

A large clinical trial shows that Keytruda is a more effective initial treatment than chemotherapy, the current standard of care, for two-thirds of patients with the most common type of lung cancer.

BEIJING— Merck MRK 0.71% & Co.’s immunotherapy cancer drug Keytruda is finding its way into China as the first imported drug approved for use under a pilot program on the resort island of ...